tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ALT Stock Latest News

Largest borrow rate increases among liquid names
The FlyLargest borrow rate increases among liquid names
7d ago
NB
ALT
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
PremiumCompany Announcements
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
14d ago
ALT
Altimmune price target lowered to $15 from $25 at Citizens JMP
PremiumThe Fly
Altimmune price target lowered to $15 from $25 at Citizens JMP
16d ago
ALT
Altimmune resumed with a Sell at Goldman Sachs
PremiumThe Fly
Altimmune resumed with a Sell at Goldman Sachs
16d ago
ALT
Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development
PremiumRatings
Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development
16d ago
ALT
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
PremiumCompany AnnouncementsAltimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
16d ago
ALT
Altimmune enrolls first patient in Restore Phase 2 trial
Premium
The Fly
Altimmune enrolls first patient in Restore Phase 2 trial
16d ago
ALT
Altimmune’s Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential
Premium
Ratings
Altimmune’s Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential
25d ago
ALT
Optimistic Outlook for Altimmune’s Pemvidutide Despite Phase 2b Setback
PremiumRatings
Optimistic Outlook for Altimmune’s Pemvidutide Despite Phase 2b Setback
25d ago
ALT
Jefferies says market reaction to IMPACT data is overkill
PremiumThe Fly
Jefferies says market reaction to IMPACT data is overkill
28d ago
ALT
Altimmune price target under review after pemvi data, says B. Riley
PremiumThe Fly
Altimmune price target under review after pemvi data, says B. Riley
29d ago
ALT
Altimmune’s Pemvi hits MASH goal, shows broad potential, says Stifel
PremiumThe Fly
Altimmune’s Pemvi hits MASH goal, shows broad potential, says Stifel
29d ago
ALT
Altimmune’s Pemvidutide: Promising Phase 2b Results Reinforce Buy Rating Amid Stock Decline
PremiumRatingsAltimmune’s Pemvidutide: Promising Phase 2b Results Reinforce Buy Rating Amid Stock Decline
29d ago
ALT
Altimmune selloff on MASH data overdone, says H.C. Wainwright
Premium
The Fly
Altimmune selloff on MASH data overdone, says H.C. Wainwright
29d ago
ALT
Altimmune Announces Positive Phase 2b Trial Results
Premium
Company Announcements
Altimmune Announces Positive Phase 2b Trial Results
29d ago
8K
ALT
Altimmune announces results from IMPACT Phase 2b trial of pemvidutide
PremiumThe Fly
Altimmune announces results from IMPACT Phase 2b trial of pemvidutide
30d ago
ALT
Altimmune to announce Topline 24 week results from Phase 2b trial of Pemvidutide
PremiumThe Fly
Altimmune to announce Topline 24 week results from Phase 2b trial of Pemvidutide
1M ago
ALT
Nucor, Charter, Senseonics, Shake Shack, Altimmune: Trending by Analysts
PremiumWeekend Updates
Nucor, Charter, Senseonics, Shake Shack, Altimmune: Trending by Analysts
2M ago
ALT
NUE
Altimmune management to meet virtually with B. Riley
PremiumThe Fly
Altimmune management to meet virtually with B. Riley
2M ago
ALT
Altimmune announces initiation of RECLAIM Phase 2 trial on pemvidutide
PremiumThe FlyAltimmune announces initiation of RECLAIM Phase 2 trial on pemvidutide
2M ago
ALT
Altimmune’s Earnings Call: NASH Trial & Financial Moves
Premium
Company Announcements
Altimmune’s Earnings Call: NASH Trial & Financial Moves
2M ago
ALT
Altimmune’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating
Premium
Ratings
Altimmune’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating
2M ago
ALT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >